Abiopharma

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

New Form 8-K/A - Jaguar Health, Inc. Filed: 2026-01-12 AccNo: 0001193125-26-010173 Size: 515 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: …

📋 Myles David C. (Officer) plans to sell 10K shares of Olema Pharmaceuticals, Inc. (at $28.34 each, total $283K) Filed: Jan 12, 2026 | ID: 000257

New Form D - CYBIN INC. Filed: 2026-01-12 AccNo: 0000912282-26-000021 Size: 12 KB

New Form 8-K/A - BIODESIX INC Filed: 2026-01-12 AccNo: 0001193125-26-010114 Size: 200 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form SC 13E3 - CYANOTECH CORP Filed: 2026-01-09 AccNo: 0000947871-26-000021 Size: 315 KB

(10% Negative) Sarepta Therapeutics Inc (SRPT) Announces Delay in revenue Trials for San Francisco Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

New Form D - Vireo Growth Inc. Filed: 2026-01-12 AccNo: 0001771706-26-000001 Size: 9 KB

(10% Negative) Lexeo Therapeutics Inc. (LXEO) Announces Delay in treatments Trials for cardiovascular diseases Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(91% Positive) Profound Medical Corp (PROF) Announces Clinical Development Update

Smith+Nephew PLC Notification

Investis Notification - Smith+Nephew PLC

New Form D - SOBR Safe, Inc. Filed: 2026-01-12 AccNo: 0001425627-26-000001 Size: 12 KB

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference